REG - Fusion Antibodies - Block listing Interim Review

Fusion AntibodiesAnnouncement

03/04/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC0081Va&default-theme=true

RNS Number : 0081V  Fusion Antibodies PLC  03 April 2023

 

3 April 2023

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Block admission six monthly return

 

Fusion Antibodies plc (AIM: FAB), a contract research organisation providing
discovery, design, and optimisation services for therapeutic antibodies to the
global healthcare market, announces the following information in connection
with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies.

 

 Name of company:                                                                Fusion Antibodies plc

 Name of scheme:                                                                 Historic options, EMI and Unapproved Employee Share Option Scheme, as

                                                                               announced on 27 September 2021

 Period of return:                                                               From 2 October 2022 to 1 April 2023

 Number and class of securities not issued under the scheme at the beginning of  757,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
 the period:

 Number of securities issued under the scheme during the period:                 Nil

 Number of options under the scheme that have lapsed during the period:          Options over 5000 Ordinary Shares
 Balance under the scheme of securities not yet issued at the end of the         752,083 Ordinary Shares
 period:

 Number and class of securities originally admitted and the date of admission:   917,083 Ordinary Shares on 27 September 2021

 Contact name and telephone number:                                              James Fair, CFO via Walbrook PR

                                                                                 +44 (0)20 7933 8780

 

 

Enquiries:

 

 Fusion Antibodies plc                                               www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                             Via Walbrook PR

 James Fair, Chief Financial Officer

 Allenby Capital Limited                                             Tel: +44 (0)20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Walbrook PR                       Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                         Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the discovery and development of
antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody design,
generation, development, production, characterisation and optimisation. These
services include antigen expression, antibody production, purification and
sequencing, antibody humanisation using Fusion's proprietary
CDRx (TM) platform and the production of antibody generating stable cell
lines to provide material for use in clinical trials. Since 2012, the Company
has successfully sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international, blue-chip
client base, which has included eight of the top 10 global pharmaceutical
companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $135.4
billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase
at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the
world's ten top selling drugs were antibody-based therapeutics with the
combined annual sales of these drugs exceeding $63.2 billion.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRZFLFXXXLZBBK